APN normalised EPS from continuing ops rises 28% on improved outlook
APN said normalised headline EPS from continuing operations grew 28% at constant exchange rates, backed by stronger Commercial Pharmaceuticals and Manufacturing EBITDA. It also cited an APAC divestment unlocking R28 billion to support buybacks and higher dividends.